Stock PEAR PEAR THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Pear Therapeutics, Inc. Stock

Equities

PEAR

US7047231052

Biotechnology & Medical Research

Delayed OTC Markets
Other stock markets
 09:30:00 2024-05-22 am EDT 		5-day change 1st Jan Change
0.000001 USD -.--% Intraday chart for Pear Therapeutics, Inc. -.--% -.--%
May. 23 Pear Therapeutics, Inc. Went Out of Business CI
May. 08 Combined Liquidation Plan and Disclosure Statement Approved for Pear Therapeutics, Inc. CI

Chart Pear Therapeutics, Inc.

Dynamic Chart

Latest news about Pear Therapeutics, Inc.

Pear Therapeutics, Inc. Went Out of Business CI
Combined Liquidation Plan and Disclosure Statement Approved for Pear Therapeutics, Inc. CI
Disclosure Statement and Plan Approved on Interim Basis for Pear Therapeutics, Inc. CI
Combined Liquidation Plan and Disclosure Statement Filed by Pear Therapeutics, Inc. CI
Third Motion for Exclusivity Period Extension Approved For Pear Therapeutics, Inc. CI
Second Motion for Exclusivity Period Extension Approved For Pear Therapeutics, Inc. CI
First Motion for Exclusivity Period Extension Approved For Pear Therapeutics, Inc. CI
First Motion for Exclusivity Period Extension Filed by Pear Therapeutics, Inc. CI
Motion for Asset Sale Approved for Pear Therapeutics, Inc. CI
Motion for Asset Sale Approved for Pear Therapeutics, Inc. CI
Asset Purchase Agreement Filed by Pear Therapeutics, Inc. CI
Asset Purchase Agreement Filed by Pear Therapeutics, Inc. CI
Notice of Auction Resluts Filed by Pear Therapeutics, Inc. CI
Bidding Procedure Approved for Pear Therapeutics, Inc. CI
Pear Therapeutics, Inc.(OTCPK:PEAR.Q) dropped from S&P TMI Index CI
More news

Analyst Recommendations on Pear Therapeutics, Inc.

Credit Suisse Downgrades Pear Therapeutics to Neutral From Outperform, Adjusts Price Target to $1 From $7 MT
TD Cowen Downgrades Pear Therapeutics to Market Perform From Outperform MT
Chardan Downgrades Pear Therapeutics to Neutral From Buy, Citing Cash Constraints, Withdraws Price Target MT
Citigroup Adjusts Price Target on Pear Therapeutics to $5 From $7, Maintains Buy Rating MT
Credit Suisse Lowers Pear Therapeutics' PT to $7 From $9, Updates Model After Q3 Actuals, Management Guidance; Keeps Outperform Rating MT
More recommendations

Press releases Pear Therapeutics, Inc.

PEAR THERAPEUTICS, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K) AQ
PEAR THERAPEUTICS FILES FOR CHAPTER 11 AND WILL SEEK TO SELL ASSETS THROUGH SALES PROCESS AQ
PEAR THERAPEUTICS, INC. : Termination of a Material Definitive Agreement, Bankruptcy or Receivership, Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement, Costs Associated with Exit or Disposal Activities, Change in Directors or Principal Officers, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) AQ
Pear Therapeutics Files for Chapter 11 and Will Seek to Sell Assets Through Sales Process BU
PEAR THERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K) AQ
More press releases

News in other languages on Pear Therapeutics, Inc.

Pear Therapeutics anuncia que ya están disponibles las versiones en español de reSET® y reSET-O®
More news

Managers and Directors - Pear Therapeutics, Inc.

Managers TitleAgeSince
Christopher Guiffre CEO
 Chief Executive Officer 56 -
Maria Sullivan CTO
 Chief Tech/Sci/R&D Officer - -
Yuri Maricich CTO
 Chief Tech/Sci/R&D Officer 44 -
Members of the board TitleAgeSince
Nancy Schlichting BRD
 Director/Board Member 69 21-11-30
Timothy A. Wicks BRD
 Director/Board Member 58 22-06-13
Corey McCann BRD
 Director/Board Member 45 21-11-30
More insiders

ETFs positioned on Pear Therapeutics, Inc.

Name Weight AuM 1st Jan change Investor Rating
ADAPTIVE RH HEDGED MULTI-ASSET INCOME ETF - USD ETF Adaptive RH Hedged Multi-Asset Income ETF - USD
0.00% 18 M€ +3.81% -
More ETFs positioned on Pear Therapeutics, Inc.

Company Profile

Pear Therapeutics, Inc. is a commercial-stage healthcare company. The Company is engaged in developing a new class of software-based medicines that is referred to as prescription digital therapeutics (PDTs), which use software to treat diseases directly. Its products include reSET and reSET-O. The Company's reSET product is indicated for the treatment of substance use disorder (SUD) as a monotherapy. Its reSET-O product is developed for the treatment of opioid use disorder (OUD) in combination with buprenorphine. The Company’s pipeline consists of product candidates in psychiatry, neurology, and outside-of-central nervous system therapeutic areas. The Company has built a portfolio of PDT product candidates that is primarily focused on psychiatric conditions.
Sector
Biotechnology & Medical Research
More about the company

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
MODERNA, INC. Stock Moderna, Inc.
+51.85% 57.87B
LONZA GROUP AG Stock Lonza Group AG
+41.42% 40.25B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-5.25% 39.94B
CELLTRION, INC. Stock Celltrion, Inc.
-5.16% 28.54B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+12.79% 26.4B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-20.18% 19.33B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+30.88% 12.4B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+0.61% 12.23B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+25.06% 12.2B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. PEAR Stock